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Abstract
Background: The effectiveness of allergen immunotherapy (AIT) in seasonal allergic 
rhinitis (AR) depends on the definition of pollen exposure intensity or time period. 
We recently evaluated pollen and symptom data from Germany to examine the new 
definitions of the European Academy of Allergy and Clinical Immunology (EAACI) on 
pollen season and peak pollen period start and end. Now, we aim to confirm the feasi-
bility of these definitions to properly mirror symptom loads for grass and birch pollen-
induced allergic rhinitis in other European geographical areas such as Austria, Finland 
and France, and therefore their suitability for AIT and clinical practice support.
Methods: Data from twenty-three pollen monitoring stations from three countries 
in Europe and for 3 years (2014-2016) were used to investigate the correlation be-
tween birch and grass pollen concentrations during the birch and grass pollen season 
defined via the EAACI criteria, and total nasal symptom and medication scores as re-
ported with the aid of the patient's hay-fever diary (PHD). In addition, we conducted 
a statistical analysis, together with a graphical investigation, to reveal correlations and 
dependencies between the studied parameters.
Results: The analysis demonstrated that the definitions of pollen season as well as 
peak pollen period start and end as proposed by the EAACI are correlated to pollen-
induced symptom loads reported by PHD users during birch and grass pollen sea-
son. A statistically significant correlation (slightly higher for birch) has been found 
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1  | BACKGROUND
Allergic rhinitis (AR) is a significant health problem due to the symp-
tom load as well as its impact to the quality of life of the affected 
part of the population. It also implies a high economic burden.1-3 The 
cause of the disease is an immunological abnormality leading to IgE-
mediated hypersensitivity reactions resulting from the exposure to 
allergens.3 The treatment of choice for dealing with the causes of AR 
rather than its symptoms is allergen immunotherapy (AIT) that aims 
to promote tolerance of the immune system toward allergens.4-7 AIT 
has been shown to be highly efficacious in the treatment of allergic 
diseases such as allergic rhinoconjunctivitis with or without allergic 
asthma,8 including improvement of symptoms, quality of life, long-
term symptom control and preventive potential.9-11 However, clinical 
effects in clinical trials demonstrated that pollen exposure has a di-
rect influence on the level of AIT efficacy measured.12
Overall, the definition of pollen season (PS) and peak pollen peri-
ods (PPP) should follow a harmonized application of pollen exposure 
criteria, taking into account biogeographical differences that may 
reflect local climate and phenology.13,14 Such a definition has been 
proposed in a recently published Position Paper of the European 
Academy of Allergy and Clinical Immunology (EAACI),15 summarized 
for birch (Betula) and grass (Poaceae) in Table 1. In the framework of 
this initiative, we have recently verified the robustness of these defi-
nitions for grass pollen in Germany, making use of 5-year measure-
ments from up to 40 monitoring stations in the country.16 Moreover, 
the correlation between birch and grass pollen concentrations and 
actual symptom loads, as reported by users of patient's hay-fever 
diary (PHD),17 during the defined birch and grass pollen seasons, has 
been demonstrated for the Berlin–Brandenburg region in Germany 
for three consecutive years: 2014, 2015, and 2016.18
Following the previous study in Germany,18 in this article we 
present the relationship between birch (Betula) and grass (Poaceae) 
pollen concentrations and actual symptom load and concomitant 
medication use, for three additional European regions in Austria, 
Finland, and France, for the same 3-year period (2014-2016) as in 
the previous research.18 As already emphasized by the expert panel, 
comprising of aerobiologists and clinicians in the respective EAACI 
Position Paper,15 the given definitions should be regarded as tenta-
tive and for critical evaluation.
Imperial College London, London, UK
9Department of Botany, Ecology and Plant 
Physiology, University of Cordoba, Cordoba, 
Spain
10Federal Office of Meteorology and 
Climatology MeteoSwiss, Zurich, 
Switzerland
11Section of Allergology, Department of 
Internal Medicine, Erasmus MC, Rotterdam, 
the Netherlands
12ALC, Allergy Learning and Consulting, 
Copenhagen, Denmark
13Center for Rhinology and Allergology, 
Wiesbaden, Germany
14Biodiversity Unit, University of Turku, 
Turku, Finland
15Finnish Meteorological Institute, Helsinki, 
Finland
16RNSA-French Aerobiology Network, 
Brussieu, France
17German Pollen Information Service 
Foundation, Berlin, Germany
Correspondence
Oliver Pfaar, Department of 
Otorhinolaryngology, Head and Neck 
Surgery, Section of Rhinology and Allergy, 
University Hospital Marburg, Philipps-
Universität Marburg, Baldingerstraße, 
35043 D-Marburg, Germany.
Email: oliver@pfaar.org
Kostas Karatzas, Environmental Informatics 
Research Group, Department of Mechanical 
Engineering, Aristotle University of 
Thessaloniki, University Campus, Box 483, 
54124 Thessaloniki, Greece.
Email: kkara@eng.auth.gr
between the Total Nasal Symptom and Medication Score (TNSMS) and the pollen 
concentration levels. Moreover, the maximum symptom levels occurred mostly within 
the peak pollen periods (PPP) following the EAACI criteria.
Conclusions: Based on our analyses, we confirm the validity of the EAACI definitions 
on pollen season for both birch and grass and for a variety of geographical locations 
for the four European countries (including Germany from a previous publication) ana-
lyzed so far. On this basis, the use of the EAACI definitions is supported in future clini-
cal trials on AIT as well as in daily routine for optimal patient care. Further evaluation 
of the EAACI criteria in other European regions is recommended.
K E Y W O R D S
allergen immunotherapy, allergic rhinitis, geographic differences, peak pollen period, pollen 
concentration, pollen season
     |  3PFAAR et Al.
This report aims to analyze whether birch and grass pollen sea-
son and peak pollen periods, as defined by the EAACI, can be iden-
tified in different regions in Europe and, more importantly, whether 
these definitions reflect the development of seasonal symptoms.
2  | MATERIAL S AND METHODS
The selection of these European regions considered the availability 
of sufficient pollen data as well as symptom data via the PHD. The 
pollen types that were included in the analysis were birch (Betula) 
and grass (Poaceae) in the years of 2014, 2015, and 2016. We there-
fore considered one region per country: the Pannonian lowlands re-
gion of Austria, the southern region of Finland, and the Rhone-Alps 
region of France. We used data from a total of twenty-three pollen 
monitoring stations (Figure 1 and Table S1).
Data of daily AR related to symptom levels and concomitant 
medication use are reported on a voluntary, regional, and ano-
nymized basis through a web-based Pollen App, which includes the 
PHD (https ://polle ndiary.com). The number of symptom reports 
was highly variable: The mean yearly number of PHD users (ie, a 
12-month period statistic, rounded to the closest integer) reporting 
symptoms for the Austrian, Finnish, and the French region was 138, 
37, and 17 for year 2014; 118, 21, and 18 for year 2015; and 106, 14, 
and 16 for year 2016.
For this study, we have considered the daily average pollen 
concentration (in pollen grains/m3) from all monitoring stations for 
birch and grass. Hereafter, the PHD data were processed in order to 
calculate the Total Nasal Symptom and Medication Score (TNSMS). 
The details of score calculation have been reported before,18 and 
the calculation is also based on prior studies.19,20 Reported symp-
toms are influenced by concomitant medication.21,22 However, dif-
ferent medication classes have different effects in improving allergic 
symptoms of patients. For this reason, we adopted a Weighted Nasal 
Medication use Score (WNMS) as reported in detail.18,20
All available data were averaged per day in order to represent 
the mean daily pollen as well as the mean TNSMS levels in all studied 
regions. To provide a data overview, basic descriptive statistics for 
the 3 years of study have been presented in Supporting information 
related to the main daily data (Table S2) and pollen season (Table S3).
A classic approach for data analysis was employed to investi-
gate the correlations between daily symptom and pollen data during 
the pollen season, following both a parametric (Pearson's r) and a 
non-parametric (Spearman's ρ) estimation. The correlation coeffi-
cients and the associated p-values, indicating statistical significance 
between the TNSMS and the pollen concentrations (for birch and 
grass), were calculated for the PS period defined with the EAACI 
definitions for each pollen type and year. Details can be found in 
the Supporting information (Appendix S1 : correlation calculations).
We also used a graphical representation of symptom data to-
gether with (a) pollen concentrations, (b) PS start and end as well as 
(c) PPP, to visually represent the temporal variation of symptoms as 
well as of pollen data for all areas and years of study and to further 
investigate their relationships (Appendix S1 S2: graphical represen-
tation and investigation of data).
3  | RESULTS
The basic descriptive statistics for the three countries are reported 
in Table S2a-c. In addition, the pollen season and peak pollen period 
start and end for both pollen types were calculated based on the 
EAACI definitions (15, Table S3a,b).
Moreover, the correlation coefficients between the TNSMS 
and the pollen concentrations (for birch and grass) were calculated 
for the period characterized from the PS start and end per pollen 
type and year (Table S4a-b). In addition, we plotted the normalized 
pollen concentration together with the TNSMS as well as with the 
total number of PHD reports per day for years 2014, 2015, and 2016 
(Figure 2 for a representative result).
A first result is related to the higher mean as well as maximum 
levels of birch pollen in the Finnish region in comparison to the 
Austrian and French regions, with a difference of one order of mag-
nitude being witnessed. The situation is reversed when it comes to 
grass, where the French and then the Austrian regions demonstrate 
a much higher mean value in comparison to the Finnish region, the 
 Pollen season
High pollen season (or “Peak 
pollen period”)
Birch Start: 1st day of 5 d (out of 7 consecutive days), 
each of these 5 d with ≥10 pollen/m3 and with a 
sum of these 5 d of ≥100 pollen/m3
End: Last day of series of 5 d (out of 7 consecutive 
days) with ≥10 pollen/m3 and with a sum of these 
5 d of ≥100 pollen/m3
Start: 1st day of 3 
consecutive days, each 
with at least ≥100 pollen/
m3
End: Last day of at least 3 
consecutive days, each 
with ≥100 pollen/m3
Grass Start: 1st day of 5 d (out of 7 consecutive days) each 
of these 5 d with ≥3 pollen/m3 and with a sum of 
these 5 d of ≥30 pollen/m3
End: Last day of series of 5 d (out of 7 consecutive 
days) with ≥3 pollen/m3 and with a sum of these 
5 d of ≥30 pollen/m3
Start: 1st day of 3 
consecutive days, each 
with at least ≥50 pollen/m3
End: Last day of at least 3 
consecutive days, each 
with ≥50 pollen/m3
TA B L E  1   Definitions of pollen seasons 
for Birch and Grass according to the 
EAACI position paper (modified from15; 
nota bene: The “high pollen days” criterion 
is not shown as it has not been analyzed in 
the current study)
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latter suggesting a relatively weaker grass pollen season. In terms 
of TNSMS, the highest mean and maximum levels are reported in 
the Finnish region, followed by the French and the Austrian regions 
under study.
The EAACI definitions 15 led to the successful identification of 
pollen seasons in all areas and for all years, for both pollen types being 
investigated. More specifically, we found that birch PS started approx. 
3-4 weeks later in the southern region of Finland in comparison to the 
Rhône-Alps region of France and the Pannonian lowlands region of 
Austria. Grass PS started approx. 6-7 weeks later in the Finnish region 
in comparison to the French region. In the Austrian region, the grass 
PS started 1-2 weeks later in comparison to the French region. The 
ending of the PS for birch arrived earlier in the Austrian and French 
regions, and is followed by the Finnish region with a delay of approx. 
4-6 weeks. PPP appeared in all areas and years, except for 2016 for 
grass and for the Finnish area. It is worth noting that in some cases like 
in the French region for grass, we identified several PPP within the PS.
Correlation of pollen concentrations and reported symptoms 
for the PS-start to PS-end period provide clear evidence concern-
ing the validity of the EAACI definitions. Both correlation coeffi-
cients appeared high and were statistically significant in most of 
the cases (Table S4a-b). The Pearson as well as the Spearman cor-
relation coefficients were higher for birch in comparison to grass in 
most of the cases, for all areas and years of study, thus suggesting 
that birch is a better indicator in comparison to grass when it comes 
to the correlation with the TNSMS for all geographic areas of study. 
Taking into account the significance level (p-value), the Pearson cor-
relation coefficient in the case of birch ranges from 0.55 (for 2016 
F I G U R E  1   Map of the locations of the pollen monitoring station at the southern region of Finland (upper right), the Pannonian lowlands 
region of Austria (lower right), and the Rhône-Alps region of France (lower left). The stations of the Berlin–Brandenburg area used for 
Germany in a previous publication (18) are also included (middle), for completeness. Map background available via Google Maps ©
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in the French region) to 0.78 (for 2014 and for the Austrian region) 
while corresponding values for grass range from 0.48 (for 2015 for 
the Finnish region) up to 0.79 (for 2014 and for the Austrian region). 
In the case of Spearman, the highest value for birch reaches 0.84 
for the Finnish region (for 2014) and for grass 0.77 for the Austrian 
region (for 2014). Overall, both coefficients suggest that the pollen 
season definitions result in high correlations in most cases between 
pollen concentrations and TNSMS levels.
The analysis showed that for the Austrian region, the maximum 
TNSMS is reached every year during the birch pollen season between 
the end of March and the mid of April. Only for 2015, the TNSMS 
reached its maximum during the last days of May and within the 
grass pollen season (where the relevant pollen concentration levels 
reached their maximum mean daily value of 161  pollen grains/m3, 
among the 3 years studied).
In the Finnish region, the peaks of TNSMS and birch pollen con-
centrations coincide in 2014 (abundant birch flowering year) and 
in 2016 (normal birch flowering year) whereas in 2015, when birch 
flowered very weakly, a similar correlation was not observed. A clear 
peak in grass pollen concentrations was detected in 2014 and 2015, 
and it was reflected in a TNSMS rise in 2015. In 2016, the grass pol-
len concentrations had multiple, albeit modest peaks.
For the French region, the TNSMS reaches its highest value 
at the beginning of June (in 2015), or at the end of May (in 2014 
and 2016), during the peak period (but not necessarily during the 
peak days, as defined in15) of grass pollen. However, TNSMS lev-
els for the birch season are slightly lower in comparison with the 
ones recorded for the grass season, with a characteristic peak in 
the middle of April, during the birch PPP (in 2015 and 2016, with 
very short peak periods) or some days before (in 2014, when the 
PPP was noticeably longer). Throughout the birch pollen season, 
the number of users reporting symptoms per day is closely aligned 
with both TNSMS levels and pollen concentrations. The picture is 
quite different for the grass pollen season: The number of symptom 
reports per day is well matched to the TNSMS levels, but both lines 
begin to rise at a time when the pollen concentrations are still low.
4  | DISCUSSION
The effect sizes of AIT as demonstrated in trials for AR depend 
on the validity of definitions of, that is, the pollen season (PS) 
start and end as well as the peak pollen period (PPP).13,15 The pol-
len flight is influenced by the characteristics and the profile of 
the flowering season, which are affected by local environment 
and climate. Pollen concentration also depends (a) on the pollen 
type: grass pollen, for example, disperses less efficiently by wind 
than birch pollen 23 and (b) on the size of the geographic area ad-
dressed (eg, the Rhône-Alps region in France is bigger than the 
Pannonian lowlands region in Austria, with 14 vs 3 pollen moni-
toring sites being included in the analysis). For this reason, pollen 
load over a geographical area might be less homogenous, resulting 
in weaker correlation between symptoms and pollen concentra-
tions. Consequently, any definition should always consider local 
conditions.13 Therefore, we evaluated the accuracy of the recently 
published EAACI definition of pollen season and pollen expo-
sure times15 of various European geographic regions and yearly 
changing of pollen concentrations. This analysis will put scientific 
ground for its application in future trials, for example, in AIT field 
studies and clinical routine.
In the frame of this analysis in three European regions and our 
recently published report of German data,18 we could confirm that 
the EAACI criteria lead to the identification of PS for all areas in 
subsequent years for birch and grass pollen. In addition, we were 
able to demonstrate that (a) the TNSMS is correlated with birch 
and grass pollen levels within the respective pollen seasons (with 
the exception of grass pollen in 2016 for Finland and France, for 
which correlation coefficients are not statistically significant; 
for the latter, however, the symptoms of users in the beginning 
of September in France may be influenced by, e.g., local ragweed 
(Ambrosia) pollen) and (b) the maximum symptom levels occurred 
mostly within the PPP following the EAACI criteria.15 This current 
calculation also underlines the feasibility of the criteria to serve 
as the basis for clinical trials in the future such as confirmatory 
F I G U R E  2   Temporal variation of the 
TNSMS, the number of PHD users, and 
the birch and grass pollen concentrations 
for 2014 (mean daily values, Pannonian 
lowlands region of Austria). The PS per 
pollen type is marked with arrows with 
a textual label. The multiple PPP starts–
ends are denoted with double arrows. 
The horizontal axis reports month start. 
The vertical axis reports the normalized 
(between zero and one) values of the 
number of PHD users, the grass, and 
birch pollen daily concentrations and the 
TNSMS
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field-based trials in AIT and for management of AR patients in the 
clinical routine. Based on our findings, the EAACI definitions for 
birch and grass are scientifically justified and sound for practical 
use. However, additional analyses on further European regions on 
a sufficient number of PHD users may also be required to account 
for local conditions and deviations.
Since PHD does not collect pollen-specific symptoms, it is ob-
vious that the symptom levels are high not only within the pollen 
season of aforementioned pollen types, but also apart from it, 
thus indicating the influence of additional parameters that affect 
the scores reported by PHD users. First, the flight of, for example, 
the birch pollen in many regions is preceded by the flight of hazel 
(Corylus) and alder (Alnus) pollen, which also possess analogue struc-
tures of the major allergen Bet v 1. This will lead to an immunological 
“priming” of the poly-allergic patients. This phenomenon has been 
shown in birch-allergic subjects experimentally in nasal provocation 
tests with the same birch pollen doses before and after birch pol-
len exposure. The above-mentioned structures of Bet v 1 in hazel 
and alder pollen may have the same effect of the priming as a birch 
pollen season itself.24 Repeated daily exposures to pollen allergens 
modify the mucosal inflammatory cell profile and in particular pro-
motes the epithelial accumulation of effector cells—which may ex-
plain high symptoms at the beginning of the birch pollen flight in 
subjects who have been exposed already to hazel and alder with Bet 
v 1 similar allergens.25
Secondly, there can be a co-seasonal pollination of other source 
allergens as in regions in France during the beginning of September 
with a natural coincidence of the grass and ragweed pollen (Ambrosia) 
flight. Also, the analysis of the region in Finland confirmed a local 
maximum around the beginning of April for all 3 years, again indi-
cating that a seasonal aeroallergen (local alder [Alnus] pollen season) 
plus possible pollen resuspension (eg, due to snow melting and road 
surface de-icing) may be the cause of this event. Overall, the number 
of users and the TNSMS in all country regions and years under inves-
tigation remarkably concur with the pollen season period, suggest-
ing that the former can be considered as a proxy of symptom level, 
while strengthening the effectiveness of the EAACI criteria for the 
PS definition for AIT and clinical practice support.
Evaluation of the criteria over several years demonstrated sta-
bility of their performance—except for the low birch season of 2015 
in Finland (Table S4a). In that year, TNSMS were not correlated with 
the birch pollen concentrations at all. An evident explanation is that 
during that year, the birch pollen concentration was not sufficient to 
induce the allergy symptoms above the noise level caused by other 
pollen and non–pollen-related factors. As a result, this season was 
not suitable for birch-related clinical trials in Finland. Noteworthy, 
the absolute concentrations in 2015 in Finland were not small if 
compared with other geographical regions (Table S2a-c). But they 
were several times lower than those in Finland during other years. 
This observation highlights the regional differences in population 
sensitivity to pollen concentrations: Tolerance to birch pollen con-
centrations in Finland is much higher than in Central Europe. The 
current season definition does not account for this variability.
One limitation of our analysis is the limited number of experi-
enced sites involved as well as the limited amount of datasets from 
patients who had to fulfill (pre-specified) inclusion criteria for re-
porting. However, the high correlation of symptom levels reported 
by PHD users with pollen concentration levels in our current anal-
ysis (as well as in our recent report 18) indeed indicates that the 
aforementioned symptom reporting is an adequate proxy of actual, 
clinically justified and valid measure of (clinically relevant) symptom 
severity.
Finally, it should be emphasized that the EAACI criteria are 
tentative and should always be evaluated with the aid of (prospec-
tively reported) actual symptom data as bioregional and environ-
mental factors indeed affect local thresholds for allergy-inducing 
pollen concentration levels.15 On this basis, it can be expected that 
for specific geographical regions in Europe the EAACI criteria may 
not always lead to the definition of a pollen season, as already sug-
gested by Karatzas et al.26 for the case of Olive (Olea) (and to some 
extend of cypress [Cupressus]) in a Mediterranean country (Greece). 
However, the results presented in this study and the previous study 
from Germany 18 clearly demonstrate the EAACI definitions for birch 
and grass to be effective and feasible in the four countries analyzed. 
Further work of the Task Force group will aim to reproduce this find-
ing in other European regions.
5  | CONCLUSIONS
The level of airborne pollen in the atmosphere is influenced by local 
environmental and climatological factors which dictate the flower-
ing phenology of species releasing pollen causing allergy. This poses 
a challenge in the effective definition of criteria for the identification 
of pollen season start and pollen season end, as well as for the iden-
tification of the peak pollen period. In a recently published Position 
Paper, a Task Force of experts of the European Academy of Allergy 
and Clinical Immunology (EAACI) comprising both aerobiologists 
and clinicians defined criteria for clinical relevant pollen “seasons” 
for a variety of plant species. To confirm these definitions, we have 
analyzed reported symptom and used medication data from the 
patient's hay-fever diary (PHD) and birch and grass pollen concen-
trations in Germany in a previous research and have found a posi-
tive and significant correlation and therefore a confirmation of the 
EAACI criteria on the regional level. In the subsequent analysis re-
ported here, we have further investigated three additional European 
regions (in Austria, in Finland, and in France) again for three subse-
quent years.
In conclusion, we identified the pollen season characteristics and 
we also confirmed a sound correlation between TNSMS and birch 
and grass pollen season start, end, and peak pollen period in all three 
European regions. Based on the current analysis and the previous re-
search, the validity of the EAACI definitions on birch and grass pol-
len season and for a variety of geographical locations is consistently 
confirmed. Their clinical use in future clinical trials on AIT as well 
as in daily clinical routine for optimal patient care is recommended.
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